Dear WIPO Re:Search Members and Friends,

Following last month’s announcement of the upcoming closure of WIPO Re:Search, I received a wonderful letter from Prof. Wellington Oyibo at the University of Lagos (Nigeria), describing the impacts of the Consortium on his institution, research, and career development. Prof. Oyibo led or co-led multiple R&D collaborations and gained broad pharmaceutical industry experience through the Consortium’s Fellowship Program. With Prof. Oyibo’s kind permission, I am pleased to share his words here:

“I wish to express my sincere appreciation and immense gratitude to the team at WIPO Re:Search and BVGH for the partnership over the years.

There is so much to say here, from personal leadership development in research and development in academia to strong capacity for leadership. I became my University's first Director of Research and Innovation, and I played very critical roles in my University's research outputs ... all courtesy of human capacity development through the programme.

I established the Patent Office before I left, and, of course, in my personal R&D research, very good research negotiation and proposals with industry, and the management of knowledge from those are fantastic takeaways from the spin-off effect on myself, institution, students, country, and the African continent. Research collaborations have been successful with partnering academic and industrial partners, and I am super delighted. These partners are still active looking for opportunities to engage in more research and development activities. This is the story, and a lot of these involved sharing of technologies that makes it exciting.

My Ph.D. students and graduates remain the great beneficiaries and is ongoing because of the strong and excellent research infrastructure that has been established over the years.

I am consolidating my work in malaria and NTD R&D and implementation and this will continue with the window now provided by BVGH.

Jennifer and her team have been fantastic, and I am confident the existing relationship will flourish with more wins and impact for the diseases we seek to eliminate.

Personally to the Director General/Coordinators of WIPO Re:Search and to Jennifer, I am grateful. Jennifer has moved solutions greatly and we remain in contact always in her various projects.”

Like Prof. Oyibo, BVGH remains dedicated to the fight against neglected diseases. We recently signed the Kigali Declaration and made three commitments to eliminating NTDs through R&D partnering and alliance management, R&D capacity building, and communications and events.

Last month, through a BVGH-coordinated collaboration, Dr. Chiaka Anumudu at the University of Ibadan (Nigeria) began her three-month fellowship at the University of British Columbia (Canada). Dr. Anumudu will be working with Dr. Horacio Bach to advance development of a schistosomiasis diagnostic.

As always, please share this Snapshot with your colleagues.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health
Cornerstones of Collaboration

Advancing Novel Drug Candidates to Combat Schistosomiasis

Schistosomiasis affects almost 240 million people worldwide. Praziquantel is the only available treatment for the disease. Reliance on a single agent for mass drug administration increases the risk that resistance will develop. New antischistosomal drugs with novel mechanisms of action are urgently needed. Prof. Conor Caffrey at the Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) screened a targeted set of inhibitors from Eisai Co., Ltd. through the Consortium and identified several hits with promising antischistosomal activity. Eisai has provided Prof. Caffrey with additional quantities of the hits for validation studies to advance his schistosomiasis drug discovery efforts.
BVGH FundFinder Featured Awards

**RIGHT Fund Product Development and Evidence Generation Awards**

Product Development grants up to 4 billion KRW per project are available for projects that aim to develop vaccines, therapeutics, biologics, or diagnostic platforms to alleviate infectious diseases with unmet health needs in LMICs. Funds requested should be commensurate with the activities outlined in the proposal. The project team must include at least one Korean entity. Collaborative submissions between Korean and non-Korean institutions are highly encouraged.

Evidence Generation grants up to 200 million KRW per project are available for projects that aim to generate evidence on the current use and gaps in the application of digital health technologies in the Global South. Funds requested should be commensurate with the activities outlined in the proposal. Collaborative submissions among multiple countries are highly welcome. The proposed project team must include at least one local institution based in the country or region that the evidence generation will focus on. Collaborative submission with a Korean entity is encouraged but not required.

Applications for both awards are due by 10:00AM KST on August 16, 2022. Learn more and apply [here](#).

**Additional Funding Opportunities**

- [Grand Challenges India Call for Proposals: Lymphatic Filariasis Diagnostics](#) – Application Deadline: July 21, 2022.
- [Mastercard Foundation Scholars Program at KNUST](#) – Application Deadline: July 29, 2022.
- [CRDF Global U.S.-Japan Cooperative Medical Sciences Program Collaborative Awards, 2022](#) – Application Deadline: July 30, 2022.
- [TWAS-BIOTEC Postdoctoral Fellowship Programme](#) – Application Deadline: August 1, 2022.
- [NIH Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)](#) – Next Letter of Intent Deadline: September 5, 2022; Next Application Deadline: October 5, 2022.
- [NIAID Contract Opportunity to Develop a Novel Vaccine Adjuvant](#) – Application Deadline: October 14, 2022.
- [Wellcome Early-Career Awards](#) – Application Deadline: October 18, 2022.
- [DAAD Scholarship Database](#) – Postgraduate scholarships for academic studies in Germany. Look [here](#) for important information for applicants.
- [Boehringer Ingelheim Fonds (BIF) Travel Grants](#) – Applications must be submitted at least six weeks, but not more than six months, before anticipated travel.
- [Institute of International Education Scholar Rescue Fund Fellowship](#) – Applications are accepted on a rolling basis; fellowships are awarded quarterly.

For more information about BVGH FundFinder, please email [Cathy Manner](#).
# Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 1-6, 2022</td>
<td>WorldLeish 7</td>
<td>Cartagena, Colombia</td>
</tr>
<tr>
<td>August 7-10, 2022</td>
<td>11th International Conference on Emerging Infectious Diseases</td>
<td>Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>August 23-25, 2022</td>
<td>9th International Toxinology Meeting</td>
<td>Oxford, UK and Virtual</td>
</tr>
<tr>
<td>September 13-15, 2022</td>
<td>Neglected Tropical Disease NGO Network Conference</td>
<td>Kathmandu, Nepal and Virtual</td>
</tr>
<tr>
<td>September 20, 2022</td>
<td>RSTMH 47th Annual Topics in Infection</td>
<td>London, UK</td>
</tr>
<tr>
<td>September 22-23, 26, 2022</td>
<td>Federation of Infection Societies International Conference</td>
<td>London, UK and Virtual</td>
</tr>
<tr>
<td>October 11-12, 2022</td>
<td>RSTMH Annual Meeting</td>
<td>Liverpool, UK</td>
</tr>
<tr>
<td>October 24-28, 2022</td>
<td>20th International Congress for Tropical Medicine and Malaria</td>
<td>Bangkok, Thailand</td>
</tr>
<tr>
<td>Oct. 30-Nov. 3, 2022</td>
<td>ASTMH Annual Meeting</td>
<td>Seattle, Washington, USA</td>
</tr>
</tbody>
</table>